1. Scrip
  2. >>Business

AbbVie’s Ex-Humira Immunology Business Is Booming

 
• By Jessica Merrill

The company raised 2024 revenue expectations, driven by the second quarter performance of its Humira successors Skyrizi and Rinvoq.

AbbVie released second quarter financial results • Source: Shutterstock

AbbVie Inc.’s big immunology growth drivers, Skyrizi (risankizumab) and Rinvoq (upadacitinib), delivered impressive growth in the second quarter, helping to offset declining sales of Humira (adalimumab) and leading the company to raise revenue forecasts for the year. The company reported second quarter sales and earnings on 25 July, including net revenues that beat the company’s expectations and analyst consensus estimates.

Key Takeaways
  • AbbVie raised revenue guidance for the year, driven by strong second quarter sales of Skyrizi and Rinvoq.
  • Humira access is expected to be more restricted in 2025, but revenues are expected to track with expectations

“Our ex-Humira growth platform, which covers more than 80% of AbbVie’s total sales, will outperform our initial full year sales guidance by more than $1bn, driven by strong performance in immunology and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.